TSLA
Tesla
-- 355.840 NVDA
NVIDIA
-- 138.850 INTC
Intel
-- 23.600 NBIS
NEBIUS
-- 44.490 PLTR
Palantir
-- 119.160 
NEWS
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Spero Therapeutics (Nasdaq: SPRO) has published data from its Phase 1 clinical trial assessing the intrapulmonary pharmacokinetics of SPR719, the active moiety of SPR720, in Antimicrobial Agents and Chemotherapy. The study, involving 33 healthy subjects, showed significant lung uptake and enhanced concentrations of SPR719 in epithelial lining fluid (ELF) and alveolar macrophages (AM).
Key findings include:
SPR719 concentrations in ELF and AM were greater than total plasma concentrations
No unexpected safety issues were observed
Results support further investigation of SPR720 as a potential oral treatment for Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD)
The company will present additional data on microbial resistance against SPR719 at IDWeek in October 2024.
Key findings include:
SPR719 concentrations in ELF and AM were greater than total plasma concentrations
No unexpected safety issues were observed
Results support further investigation of SPR720 as a potential oral treatment for Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD)
The company will present additional data on microbial resistance against SPR719 at IDWeek in October 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
8158
Followers
50
Following
93K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call